CompletedPhase 3NCT00681486
Ghrelin - A Possible Opportunity to Improve Appetite
Göteborg University30 participantsOct 2003 to Jul 2008
Cancer
Compare peptides
Compare two to four peptides side by side. Counts are exact.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural peptide Ghrelin (human), ghrelin-28 | Synthetic analog Ipamorelin | |
|---|---|---|---|
| Identity | |||
| Kind | Natural peptide | Synthetic analog | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | No results yet | 110 | |
| Evidence level | No study resultsRegistered trials, no results from human studies | Has results from studies in people | |
| Safety | |||
| Safety results | No safety results | 1 (1 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 3 | 21 more mentions it but does not test it | |
From the regulatory data of each peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
No outcome group has study results for two or more of these peptides.
PepBank is a research reference. Talk to a doctor before you use any peptide.
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Ipamorelin differs from Ghrelin (human), ghrelin-28 at 5 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
3 trials · 3 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)
Göteborg University30 participantsOct 2003 to Jul 2008
Cancer
University of Pennsylvania5 participantsMay 2012 to Dec 2012
The Frailty Syndrome
University of Pennsylvania5 participantsFeb 2013 to Jun 2013
Frailty in Aging
2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)
Helsinn Therapeutics (U.S.), Inc320 participantsApr 2011 to May 2014
Gastrointestinal Dysmotility
Helsinn Therapeutics (U.S.), Inc117 participantsApr 2008 to Dec 2009
Ileus
1 more mentions it but does not test it. They only measure it or name it in their text.